

Press Release

Leif Heussen Corporate Communications

Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-4030 F +49 6172 608-2294 leif.heussen@fresenius.com

January 23, 2025

Fresenius signs agreement with Microsoft to boost companywide collaboration and IT security

Fresenius has signed a new five-year global contract with Microsoft focused on collaboration and IT security for all Fresenius employees. Starting in June 2025, the contract will encompass tools such as Microsoft Defender, Microsoft 365, SharePoint, OneDrive, and Microsoft Power BI, combining the license demands of all Fresenius segments under one agreement. The objective is to streamline and simplify daily office operations for employees while enhancing security capabilities.

"This contract represents another milestone and is a substantial improvement to our IT foundation. We are moving to a comprehensive and state-of-the-art ecosystem across all segments," says Ingo Elfering, Chief Information Officer of the Fresenius Group.

The collaboration between Fresenius and Microsoft, expanding since 2022, focuses on cloud computing, security features, collaboration features and AI enablement. It has facilitated successful large-scale cloud migrations at Fresenius and established the groundwork for further innovation and change initiatives.

"Our Microsoft technology helps Fresenius to focus more on their customers and patients and less on IT management. Security and data protection are our top priorities in its development. Microsoft plays a central role in the digital ecosystem, and this comes with a critical responsibility to earn and maintain trust, especially in healthcare", explains Michael Sahnau, Director Health & Life Science at Microsoft Germany.

Looking ahead, the collaboration will enhance the capabilities especially of Fresenius' Helios Group with advanced Artificial Intelligence adoption and new cloud technologies. It will also expand across all of Fresenius cloud migration strategy and a modern, harmonized, and cost-efficient IT framework.

#

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2023 fiscal year, Fresenius generated €22.3 billion in annual revenue. Fresenius offers solutions to the social challenges posed by a growing and ageing population and the resulting need for affordable, high-quality healthcare. Fresenius currently counts over 175,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as the investment company Fresenius Medical Care. With 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi's product portfolio includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and generic intravenous drugs. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people's health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the Company's website at <u>www.fresenius.com</u>. Follow us on social media: <u>www.fresenius.com/socialmedia</u>

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852 Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser Chairman of the Supervisory Board: Wolfgang Kirsch